NUVAIRA, INC. — SEC Form D Filing
NUVAIRA, INC. filed an SEC Form D on March 4, 2026, reporting $35.76M raised in Health Care.
Form D filing details
- Filing
- SEC Form D
- Filing date
- March 4, 2026
- Amount reported
- $35.76M
- Round stage
- Seed
- Industry
- Health Care
- Website
- https://nuvaira.com/
What the company does
Securities: Equity, Conversion of SAFEs; Conversion of debt. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Patients with COPD often face persistent symptoms and are limited by existing therapies that may not provide sufficient relief.
Solution
NUVAIRA offers a one-time lung denervation procedure aimed at improving lung function and reducing symptoms in COPD patients.
Why now
There is a growing demand for effective, long-lasting treatment options for COPD as current therapies are often inadequate.
Verdict
Investors backed Nuvaira at this moment because the need for innovative COPD treatments is pressing, aligning with rising healthcare demands, not because existing therapies were seen as broadly effective. They were implicitly betting on the efficacy of a novel singular approach to lung denervation that could disrupt traditional treatment paradigms. However, the limited upside arises from the significant risk of slow adoption due to entrenched medical practices and skepticism, challenging long-term market penetration.
Source: SEC EDGAR Form D filing